---
title: "GLP-1 Receptor Agonists Show No Increased Cancer Risk in Endogenous Cushing’s Syndrome"
id: "endocrine-news-0-new-research-greenlights-popular-obesity-medications-for-high-risk-cushing-s"
canonical_url: "https://medichelpline.com/clinical-feed/endocrine-news-0-new-research-greenlights-popular-obesity-medications-for-high-risk-cushing-s"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "Endocrine News"
source_url: "https://endocrinenews.endocrine.org/new-research-greenlights-popular-obesity-medications-for-high-risk-cushings-syndrome/"
published_at: "2026-08-03T11:52:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# GLP-1 Receptor Agonists Show No Increased Cancer Risk in Endogenous Cushing’s Syndrome
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/endocrine-news-0-new-research-greenlights-popular-obesity-medications-for-high-risk-cushing-s
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** Endocrine News
- **Source URL:** [Original Journal Publication](https://endocrinenews.endocrine.org/new-research-greenlights-popular-obesity-medications-for-high-risk-cushings-syndrome/)
- **Published At:** 2026-08-03T11:52:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- A nationwide, real-world cohort study found no increased risk of malignancy associated with exposure to **GLP-1 receptor agonists** in patients with endogenous **Cushing’s syndrome**. - The analysis, published in The Journal of Clinical Endocrinology & Metabolism, used data from Israel’s Clalit Health Services covering diagnoses from 2000–2023. - The cohort comprised 609 patients with endogenous Cushing’s syndrome (ectopic and adrenal carcinoma cases excluded) and an average follow-up of 14.7 years. - 137 patients (22.5% of the cohort) were prescribed and consistently used GLP-1 medications during the study period. - Across the full cohort, 116 patients developed cancer and 141 patients died during follow-up. - Time-varying analyses accounting for the timing of medication initiation found no statistically significant association between GLP-1 exposure and incident malignancy; the crude hazard ratio was 1.65 and the adjusted hazard ratio was 1.22 (not statistically significant). - Secondary sensitivity checks, including a 12-month lag after treatment initiation and stratification by remission status, produced consistent results supporting oncologic safety. - Authors conclude the findings provide important evidence supporting the **oncologic safety** of GLP-1 receptor agonists in this high-risk population and suggest clinicians may prescribe these agents to address severe metabolic complications of Cushing’s syndrome. - Specific details about which confounders were included in the adjusted model were not reported in the summary of the source article.
## Clinical Analysis & Structured Key Points
[Skip to content](https://endocrinenews.endocrine.org/new-research-greenlights-popular-obesity-medications-for-high-risk-cushings-syndrome/#wp--skip-link--target) [Endocrine News](https://endocrinenews.endocrine.org) [![Endocrine News](https://endocrinenews.endocrine.org/wp-content/uploads/es-reversed.svg)](https://endocrinenews.endocrine.org/) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) Search Search [Current Issue Download](https://endocrinenews.endocrine.org/magazine-issues/july-2026/) [Login](https://endocrinenews.endocrine.org/auth/login/?redirect=https://endocrinenews.endocrine.org/new-research-greenlights-popular-obesity-medications-for-high-risk-cushings-syndrome/) ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/Endocrine_News_standard_logo.svg) * * * # New Research Greenlights Popular Obesity Medications for High-Risk Cushing’s Syndrome By Jackie Oberst August 3, 2026 Print this article Share this article ![](https://endocrinenews.endocrine.org/wp-content/uploads/PensTape.jpg) Popular diabetes and weight-loss medications known as GLP-1 receptor agonists do not increase the risk of cancer in patients with endogenous Cushing’s syndrome, according to a comprehensive nationwide study titled, “**[GLP-1 Recetor Agonist Exposure and Malignancy Risk in Patients with Endogenous Cushing’s Syndrome](https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/clinem/dgag223/8700559?redirectedFrom=fulltext)** ,” and published in _The Journal of Clinical Endocrinology & Metabolism_. The findings offer critical clinical reassurance for a highly vulnerable patient population prone to both severe metabolic disorders and elevated cancer risks. Endogenous Cushing’s syndrome is a rare endocrine disorder driven by the body’s overproduction of the hormone cortisol. This chronic hypercortisolism frequently disrupts glucose metabolism, triggering severe insulin resistance, obesity, and type 2 diabetes in roughly a third of all patients. While GLP-1 receptor agonists — a drug class that includes widely used medications like semaglutide and liraglutide — have become a gold standard for managing weight and blood sugar, their safety profile in Cushing’s patients had remained largely unknown until now. Because individuals with Cushing’s syndrome already face a baseline elevated risk of developing malignancies, medical professionals have long anticipated concrete safety data before broadly prescribing these therapies. > The study authors concluded that these findings supply vital evidence establishing the oncologic safety of GLP-1 receptor agonists within this specialized population. As a result, endocrinologists can more confidently prescribe these highly effective metabolic tools to combat the severe diabetes and obesity that frequently impair the quality of life for Cushing’s syndrome patients. To evaluate this risk, a team of international medical researchers analyzed real-world medical data spanning more than two decades from Israel’s Clalit Health Services database. The cohort included 609 patients diagnosed with endogenous Cushing’s syndrome between 2000 and 2023, excluding those with ectopic forms or adrenal carcinomas. Over an extensive average follow-up period of 14.7 years, researchers closely monitored the patients for the onset of new cancers while factoring in competing risks like overall mortality. The statistical data revealed that 137 patients — comprising 22.5% of the total cohort — were prescribed and consistently took GLP-1 medications. Throughout the duration of the multi-year study, a total of 116 patients across the entire group developed cancer, and 141 individuals passed away. Using an advanced time-varying analytical framework to account for the exact timing of when patients started their medication, the researchers found no statistically significant correlation between GLP-1 exposure and an increased probability of developing a malignancy. The crude hazard ratio initially sat at 1.65, but after adjusting for confounding health variables, the adjusted hazard ratio dropped to an entirely non-significant 1.22. To ensure the robustness of their conclusions, the investigators performed secondary sensitivity analyses. This included implementing a strict 12-month lag period following the initiation of the drug to ensure pre-existing, undiagnosed cancers did not skew the data. They also stratified the results based on whether a patient’s Cushing’s syndrome was currently in remission. Both secondary checks yielded identical results, solidifying the evidence that the therapy does not trigger or accelerate tumor development. The study authors concluded that these findings supply vital evidence establishing the oncologic safety of GLP-1 receptor agonists within this specialized population. As a result, endocrinologists can more confidently prescribe these highly effective metabolic tools to combat the severe diabetes and obesity that frequently impair the quality of life for Cushing’s syndrome patients. * * * ## TOPICS IN THIS ARTICLE: [GLP-1s](https://endocrinenews.endocrine.org/category/glp-1s/) ←[CMS Releases Annual Physician Payment Proposed Rule; Physician Payment Reform Legislation Introduced in the House ](https://endocrinenews.endocrine.org/cms-releases-annual-physician-payment-proposed-rule-physician-payment-reform-legislation-introduced-in-the-house/) ## RELATED ARTICLES * ### [ CPAP Therapy Reverses Low Testosterone in Men with Severe Obesity, Independent of Weight Loss ](https://endocrinenews.endocrine.org/cpap-therapy-reverses-low-testosterone-in-men-with-severe-obesity-independent-of-weight-loss/) July 8, 2026 * ![Growth Therapies Fall Short for Girls with Classical CAH](https://endocrinenews.endocrine.org/wp-content/uploads/jcem_110_1cover-1-777x1024.jpeg) ### [ Growth Therapies Fall Short for Girls with Classical CAH ](https://endocrinenews.endocrine.org/growth-therapies-fall-short-for-girls-with-classical-cah/) July 7, 2026 * ![Denosumab Triggers Paradoxical Hungry Bone Syndrome-Like State in Multiple Myeloma Patient](https://endocrinenews.endocrine.org/wp-content/uploads/jcemcr_2_5cover-765x1024.jpeg) ### [ Denosumab Triggers Paradoxical Hungry Bone Syndrome-Like State in Multiple Myeloma Patient ](https://endocrinenews.endocrine.org/denosumab-triggers-paradoxical-hungry-bone-syndrome-like-state-in-multiple-myeloma-patient/) July 6, 2026 * * * ADVERTISEMENT ![July 2026](https://endocrinenews.endocrine.org/wp-content/uploads/JULYCOVERproof002-765x1024.jpg) [View Archives](https://endocrinenews.endocrine.org/magazine-issues/) ADVERTISEMENT ADVERTISEMENT ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/scientists_optim-1024x569.jpg) ## Join the Global Movement Advancing Endocrine Science and Medicine Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities. [Join Today](https://www.endocrine.org/membership) [![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/Endocrine_Society_Logo.webp)](https://www.endocrine.org/) ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/Endocrine_News_standard_logo.svg) [![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/facebook.svg)](http://www.facebook.com/pages/The-Endocrine-Society/93758955863)[![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/x.svg)](https://x.com/TheEndoSociety)[![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/linkedin.svg)](https://www.linkedin.com/company/the-endocrine-society/) ## Research * * * ### Health Topics [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) [Transgender Health](https://endocrinenews.endocrine.org/category/health-topic/transgender-health/) ### Patient Populations [](https://endocrinenews.endocrine.org/category/health-topic/adrenal/)[Health Disparities](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) [About Endocrine News](https://endocrinenews.endocrine.org/about-endocrine-news/) [Advertise in Endocrine News](https://endocrinenews.endocrine.org/advertise/) [Contact Us](https://endocrinenews.endocrine.org/contact-us/) [About the Endocrine Society](https://endocrinenews.endocrine.org/about-endocrine-news/) [Privacy Policy](http://www.endocrine.org/about-us/privacy-policy) [Terms of Use](http://www.endocrine.org/about-us/terms-of-use) © 2026 Copyright Endocrine Society. All rights reserved. 2055 L Street NW, Suite 600 | Washington, DC 20036 Phone: 202.971.3636 | Toll-free: 888.363.6274 Website Design and Development by [**Matrix Group International**](https://www.matrixgroup.net/) [Back to Top](
## Related Clinical Research

- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)
- [SGLT2 inhibitors vs GLP-1 RAs and osteoarthritis risk in type 2 diabetes: a multi-institutional co](https://medichelpline.com/clinical-feed/plos-one-16-comparative-effects-of-sglt2-inhibitors-and-glp-1-receptor-agonists-on.md)
- [Moving Forward: The Future of GLP-1 Therapies](https://medichelpline.com/clinical-feed/endocrine-news-18-moving-forward-the-future-of-glp-1-therapies.md)
- [No Patient Left Behind: Expanding Semaglutide’s Reach](https://medichelpline.com/clinical-feed/endocrine-news-21-no-patient-left-behind-expanding-semaglutide-s-reach.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.